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1. INTRODUCTION 
Under physiological conditions, angiogenesis is activated in response 
to low oxygen level. The process is regulated by the HIF (hypoxia-
inducible factor) complex. In case of hypoxia, the HIF alpha and beta 
subunits form a complex, recruits its co-activator, p300/CBP (CREBB 
Binding Protein) and binds to the Hypoxia Responsive Element of the 
target genes, thus modifying their transcription. Several of these target 
genes are responsible for inducing angiogenesis in order to increase 
the oxygen delivery of the tissue. VEGF (vascular endothelial growth 
factor) is considered to be the key hypoxia dependent cytokine for 
endothelial sprouting. Besides, many other factors are also able to 
positively influence the process of angiogenesis such as platelet-
derived growth factors (PDGFs), fibroblast growth factors (FGFs), 
placental growth factor, angiopoietins, Jagged, epidermal growth 
factor, hepatocyte growth factor and interleukin-8.  
These ligands bind to their receptors on the surface of endothelial 
cells. Binding the growth factor leads to the activation of signaling 
cascades, influencing the survival, proliferation and migration of ECs 
and thus the maintenance of existing- and development of new 
vessels. Moreover, these pathways regulate further processes involved 
in angiogenesis, such as secretion of additional growth factors, 
upregulation of angiogenic receptors, alterations in cell-cell and cell-
matrix interactions by matrix metalloproteinases, and activation of the 
members of endothelial cell adhesion molecule family.  
The healthy body controls angiogenesis by balancing a series of 
angiogenesis stimulating and inhibiting factors. By overexpressing the 
angiogenesis stimulating factors, blood vessel growth becomes highly 
intensive in some pathological conditions, including cancer. 
In 1971, Judah Folkman assumed that malignant cells secrete 
proangiogenic factors in order to ensure that tumors reaching about 2 
mm diameter access the necessary amount of oxygen and nutrients by 
developing their own blood supply. Moreover, by regulating the 
expression of HIF and/or other proangiogenic factors, the presence of 
different oncogenes or loss of function of tumor suppressor genes can 
also facilitate tumor induced angiogenesis. 
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The most important molecules regulating neovascularization are 
RTKs, such as VEGFRs, PDGFRs, FGFRs, and the TIE receptors. 
Besides, serine-threonine kinases, such as the members of TGF 
receptor family also regulate the process of angiogenesis. Other 
receptors exert angiogenesis stimulation not by phosphorylating 
partner molecules, but by enhancing the effects of potential 
transcriptional activators, such as the Notch receptor family.  
Beside endothelial sprouting driven by the VEGF-VEGFR axis, 
alternative vascularization mechanisms, which cannot necessarily be 
regulated by the main angiogenic molecules also exist. These 
processes include intussusceptive angiogenesis, vessel incorporation, 
glomeruloid angiogenesis, postnatal vasculogenesis and vasculogenic 
mimicry.  
Because of the dominance of the proangiogenic factors in malignant 
tissues, tumor blood vessels differ from the normal ones both in 
function and structure. In a healthy adult the normal vasculature is 
static, the ECs have long half-life, they are located on a well defined 
basal membrane (BM), linked with cell junctions and stabilized by 
pericytes and vascular smooth muscle cells (VSMC). Maintenance of 
the vessel is secured by autocrin signals and the presence of signals 
from oxygen sensors provide appropriate blood flow. In contrast, 
tumor blood vessels usually have deficient pericyte and VSMC 
coverage. The BM is often degraded, the morphology of ECs are 
changed, and cell-cell junctions are often lost. As a result, vessels get 
dilated negatively impacting the ratio of vessel surface, which supplies 
the tumor tissue with oxygen and nutrients. The loosening of the 
signals of oxygen sensors, eventually leads to abnormal blood flow in 
the tumor vasculature. The degraded BM not only leads to enhanced 
metastatization capacity and the possibility of the creation of mosaic 
blood vessels, but vessels get hyperpermeabilized as well, causing an 
increase in the interstitial fluid pressure, which cannot be restored 
because of the decreased lymphatic function. Thus, the oxygen supply 
of the tumor decreases, resulting in an increased glycolytic activity to 
provide energy and the necessary building material for the growing 
tumor. The altered acidic microenvironment selects for hypoxia 
resistant, aggressive tumor cells, and further supports the invasion and 
metastatization ability of malignus cells, creating a vicious circle in 
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tumor progression. Moreover, as a result of the inadequate blood flow, 
the resulting hypoxia and/or the tightened BM, efficacy of 
conventional anticancer therapies are inadequate due to limited 
penetration. These abnormalities of tumor blood vessels and the 
resulting aggressiveness of cancers, accompanied by decreased 
efficacy of conventional treatment led Rakes Jain to the elaboration of 
the vessel normalization theory. Accordingly, the inhibition of the 
signal of proangiogenic factors and the subsequent normalization of 
tumor blood vessels has become a critical step in cancer therapy. 
The following molecules are identified as antivascular agents:  
Conventional therapeutic drugs have been found to have 
antiangiogenic functions as "side effect". Vascular disrupting agents 
selectively target tumor vessels, causing fast and dynamic effects. 
They destroy rapidly dividing ECs in the tumor tissue by targeting the 
colchicine binding site of tubulins or induce vascular collapse through 
TNF-α. As a result, the vascular supply shuts down, causing 
necrotization as a response of insufficient oxygen and nutrient 
delivery. Vasoactive agents combinatorially block existing vessels and 
suppress the formation of new ones. Moreover, they do not seem to 
preferentially target the larger vessels in the tumor center, but also the 
small ones in the periphery, causing hyperabnormalization and 
hyperpermeability of the vessels. This allows chemotherapeutic agents 
better access to the tumor. However, these drugs are highly toxic 
when administered systemically, thus local, small dose and 
metronomic application is preferable. 
Angiogenesis inhibitors block the formation of new vessels from 
preexisting ones, but do not affect already established vasculature. 
They are thought to mainly act on small vessels of the tumor edge, 
mostly at the early stage of tumorigenesis or metastatization. In the 
absence of selective HIF inhibitors and the presence of a number of 
factors that also regulate the expression of angiogenic cytokines in 
tumors, the common way is to target molecules downstream of HIF by 
the blockade of receptor - growth factor communication.  
Growth factors can be targeted with either monoclonal antibodies 
(mABs) or soluble „trap/decoy” receptors. Receptors on ECs can be 
targeted at their extracellular domain by mABs, thus blocking ligand 
binding, or by RTKIs at the tyrosine kinase domain of the proteins, 
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which serve as docking sites for molecules mediating the angiogenic 
signal.  
Initially, no resistance to antiangiogenic tyrosine kinase inhibitors was 
expected, because they target ECs which are genetically stable and 
therefore unlikely to develop mutations. In spite of that, drug 
resistance in patients treated with antiangiogenic therapies is an 
important clinical problem. Both primary (no initial response is shown 
to therapy) and secondary (after a short regression period, the tumor 
recovers) resistances have been documented. There is a substantial 
volume of literature on the potential mechanisms that can lead to 
tumor resistance against antiangiogenic RTKIs. These include 
hypoxia-driven mechanisms, the activation of compensatory 
angiogenic molecular pathways, the mobilization of myeloid or 
endothelial progenitor cell populations, the downregulation of target 
receptors in endothelial or tumor cells and also a switch to an 
alternative vascularization mechanism. Although suboptimal 
pharmacokinetics have also been described, so far most studies 
dealing with antiangiogenic RTKIs and drug resistance in solid tumors 
have focused on the above mechanisms.  
Although ADME can fundamentally influence the therapeutic benefit 
of different drugs, until recently, extensive ADME studies were 
conducted rather late in the process of drug development, mainly in 
phase I clinical studies. This may be one of the key factors behind the 
low, 11%, overall first-in-man to registration rate of novel drug 
candidates in the 1990s. This proportion was especially poor (5%) 
among drugs in the field of oncology. 
Mass spectrometry is a powerful technique, enabling the parallel 
determination of label-free drugs and their metabolites from different 
tissue compartments, that gives researchers the opportunity to analyze 
the adsorption, distribution and elimination of the native drug and its 
active/toxic metabolites as well.  
Although the role of VEGF and its receptor in the growth, 
vascularization, and metastatization of colorectal cancer is already 
known since the 1990s, and a number of antiangiogenic molecules are 
approved to treat these conditions, no classical antiangiogenic RTKI is 
effective in that kind of cancers.  
 
6 
 
2. AIMS 
 
The clinical experiences with antiangiogenic RTKIs are controversial, 
despite their predicted inhibitory and normalizing effects on vessel 
growth. No biomarker of tumor response has yet been linked to the 
effect of these agents. Taken into consideration that ADME can 
fundamentally influence the therapeutic benefit of different drugs, the 
following specific aims have been defined:  
 
1. to develop a method for the detection of antiangiogenic RTKIs 
and their metabolites in different tissues. 
2. to analyse the distribution and levels of different antiangiogenic 
receptor tyrosine kinase inhibitors (RTKIs) inside subcutaneous 
murine tumors growing in mice by using MALDI-MSI. 
3. to evaluate the potential associations between intratumoral 
antiangiogenic drug levels and distributions and 3.1./ tumor 
growth inhibition; 3.2./ blood vessel density and area; 3.3./ 
blood vessel integrity (basement membrane, pericyte and α-
smooth muscle actin (SMA) coverage 3.4./ the size and 
localization of hypoxic areas of the tumor tissue; 3.5./ the 
expression and distribution of receptors targeted by the RTKIs. 
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3. METHODS 
 
Tumor models 
Two different mouse colon adenocarcinoma models, C26 and C38 
were used for our experiments.  
The C26 cell line was cultured in RPMI 1640 medium with 10% fetal 
bovine serum and 1% penicillin/streptomycin in a humidified 
atmosphere at 37°C, 5% CO2. Groups of six female Balb/C mice were 
inoculated subcutaneously (s.c.) with 2x106 C26 cells.  
The C38 tumors were maintained by serial s.c. transplantations of 
tumor cubes measuring 5×5×5 mm, and at last transplanted into 
female C57black/6 mice for our experiments.  
 
Drugs 
For drug treatment of C26 bearing mice, 5 antiangiogenic RTKIs 
either approved by both the FDA and the EMEA (pazopanib, 
sorafenib, sunitinib) or investigated in Phase III trials (motesanib, 
vatalanib) were selected. In the C38 model a vatalanib-treated and a 
control group was generated. These RTKIs are known to have 
significant IC50 values of the main angiogenic receptor, VEGFR2, 
and may also inhibit PDGF- and FGF receptors. 
Drugs were suspended in 2% carboxymethylcellulose with 2 mg/mL 
methyl-4-hydroxibenzoate. Control animals received the suspending 
medium only.  
 
Treatments 
RTKI treatments began 2 weeks after tumor cell injection in case of 
the C26 model and 9 days after C38 tumor implantation and were 
performed once daily at a dose of 100 mg/kg per os with a feeding 
tube 5 times a week for two weeks. 
Tumor size was measured three times a week with a caliper and 
expressed in mm3 by the formula for the volume of a prolate ellipsoid 
(length x width2 π/6) in case of both models.  
To assess intratumoral hypoxia, a bolus of i.p. pimonidazole (60 
mg/kg) was administered 2 hours before the mice were sacrificed. 
Two hours after the last RTKI treatment, blood was drawn from the 
8 
 
canthus and the animals were sacrificed. Tumors were removed and 
snap frozen.  
 
Analysis of vascular parameters and target receptors 
For the analysis of RTKI distributions, vascular parameters and target 
receptor expressions, 10 serial frozen sections were cut from each 
tumor. Sections #5 and #7 were used to analyze the distribution and 
levels of the given RTKI by MALDI-MSI and for subsequent 
haematoxylin&eosin (HE) staining. Sections #1-4 were labeled with 
either of the following primary antibodies: anti-FGFR1, anti-
PDGFRα, anti-PDGFRβ and anti-VEGFR2. For hypoxia detection 
(section #6), we used the Hypoxyprobe-1 Plus Kit. Sections #8-10 
were labeled with either of the following primary antibodies: anti-
laminin (for endothelial basement membrane labeling), anti-desmin 
(for pericyte labeling) and anti-α-smooth muscle actin (anti-αSMA). 
All of the above primary antibodies were developed with an 
appropriate fluorescent secondary antibody. For intratumoral 
microvessel density and area measurements, sections #1-4, #6 and #8-
10 were co-stained with anti-mouse CD31 antibody, followed by a 
counterstain with Hoechst 33342 before mounting under glass 
coverslips in ProlongGold Antifade Reagent.  
Slides were scanned by TissueFAXS and analyzed by ImageJ and 
TissueGnostics 4.0.0140 softwares.  
Microvessel densities and areas were then calculated by counting the 
number of blood vessels or the CD31-positive pixels in the total area 
of ten intratumoral regions from the living part of the tissue. The 
percentages of microvessels that were positive for laminin, desmin or 
αSMA were also calculated. For quantification of hypoxia and 
PDGFRα, PDGFRβ and FGFR1 expressions, the percentages of 
hypoxic regions and positively labeled cells were determined across 
the entire area of section. VEGFR2 density was calculated by 
counting the VEGFR2 positive tumor cells and blood vessels, and for 
quantification of VEGFR2 area, the pixel number of tumor images 
that were occupied by VEGFR2 positive endothelial or tumor cells 
were calculated on 10 viable tumor regions.  
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Compound characterization 
For compound characterization drugs were dissolved in 50% methanol 
at 0.5 mg/mL concentration. The matrix, 7.5 mg/mL α-cyano-4-
hydroxycinnamic acid was dissolved in 50% acetonitrile and 0.1% 
trifluoroacetic acid. 1μL of the compound solution was applied with 
1μL matrix solution to the MALDI plate. Full mass spectra were 
obtained by using a MALDI LTQ Orbitrap XL mass spectrometer at 
60,000 resolution in positive polarity mode. The spots were sampled 
in survey mode collecting 20 experiments for a single run. The 
nitrogen laser was set to 10 μJ. The detected precursor ion was 
fragmentized by using 40% normalized collision energy (NCE) during 
a 30 ms activation time, while activation Q of 0.25 was applied. The 
precursor ions were isolated with m/z 2.0 width and MS/MS spectra 
were collected at normal scan rate in centroid mode.  
 
Tissue imaging of antiangiogenic RTKIs 
10-μm frozen sections were cut using a cryotome and placed onto 
glass slides. After drying of the tissue, 0.5 mL matrix solution was 
applied stepwise to avoid wetting of the sections by using an airbrush, 
while its position was kept constant. Full mass spectra were collected 
by using the Orbitrap mass analyzer at 60,000 resolution (at m/z 400) 
in positive mode with a 150−800 Da mass range with activated 
automatic gain control mode. Tissue sections were sampled with 100 
μm raster size. The nitrogen laser was operated at 10.0 μJ. For 
obtaining MS/MS data, the observed peaks of the precursor 
antiangiogenic drugs were isolated with m/z 2.0 width isolation 
window and fragmentized, using 40% NCE, 30 ms activation time and 
0.25 activation Q. For MS/MS spectra generation, the minimal signal 
required was 500 counts. The fragment ions were analyzed in the 
linear ion trap at normal scan rate. Evaluation of the spectra was 
performed with Xcalibur v 2.0.7. software, while the visualization of 
drugs, metabolites and fragment ion distribution was implemented 
with the ImageQuest™ software. 
 
Quantification of the precursor compounds 
For tissue quantification of intratumoral drug concentration, 
calibration curves of each compound were established on tissue 
10 
 
sections of untreated control C26 and C38 tumors. Drugs were 
dissolved and diluted in 50% methanol (concentration range: 0.001–
0.5 μmol·mL−1) and 0.5 μL from each concentration was applied on 
the tissue section. Spraying and detection conditions were the same as 
those during the tissue section analysis of in vivo treated tumors. 
Average signal intensities of the applied concentrations were 
measured and normalized to total ion current by using Xcalibur v 
2.0.7. and ImageQuest™ softwares. Calibration curves were created 
and then used to estimate the tissue drug concentrations of in vivo-
treated tumor sections. 
 
Compound detection in the blood 
20μL plasma samples were collected and proteins were removed by 
acetonitrile precipitation. Pierce C18 Tips were used to concentrate 
the RTKIs from the precipitated plasma samples following the 
manufacturer’s instructions. 1μL of the sample was applied on the 
MALDI plate with 1μL matrix solution using the same instrument 
settings as those for the compound characterization.  
Throughout our MS experiments drugs were considered to be 
identified if both the precursor molecule and at least one fragment ion 
were discovered in the spectra.  
 
Statistical analysis  
Differences in parametric and non-parametric variables between 
multiple groups were analyzed using ANOVA and Dunnett's posthoc 
test or using the Kruskal–Wallis test followed by a posthoc Dunn’s 
multiple comparison test, respectively. For comparing two groups, t- 
or Mann-Whitney U tests were applied. Differences were considered 
statistically significant when p<0.05. All statistical analyses were 
carried out using GraphPad Prism 5.0 software.  
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4. RESULTS 
 
Tumor growth inhibition  
A significant relative tumor growth inhibitor effect was shown after 
two weeks of RTKI treatment, when comparing the % change in 
tumor volume in the C26 model. Sunitinib was the only drug affecting 
tumor growth in this experimental setting.  
In the C38 model, two weeks of vatalanib treatment significantly 
reduced tumor burden. 
 
Immunohistochemical analysis 
The growth of s.c. tumors in mice is known to be angiogenesis-
dependent. Thus, in the next step of the experiment we tested, if the 
differences in tumor growth are in line with the effects of drugs on 
vascular parameters and the expression of target angiogenic receptors 
of the RTKIs. Therefore, we stained tissue sections for these 
parameters.  
The expression level of antiangiogenic RTKs may significantly 
influence treatment response, and in turn, successful therapy can also 
regulate target receptor localization and function. In the C26 model 
expression of PDGFRα, -β and FGFR1 was observed not only in 
mural cells, but also on tumor cells. Expression patterns of PDGFRα, -
β and FGFR1 did not change in response to treatment with any of the 
compounds in the C26 model. C38 tumor cells did not express the 
aforementioned receptors, but a definite cell population expressing 
PDGFRα, -β and FGFR1 was detectable on the mural cells. Similarly 
to the C26 model, no change in the expression of PDGFRα, -β and 
FGFR1 was seen. 
VEGFR2 expression was detected both on tumor and endothelial cells 
in the C26 model. Significant differences were shown both when 
counting the VEGFR2 signal and when measuring the area of 
VEGFR2+ cells in C26 tumors. The post-hoc test showed that 
VEGFR2 expression was altered only in the sunitinib treated group. 
C38 tumors were characterized by a weak VEGFR2 expression of the 
CD31+ endothelial layer, but no signal of the receptor on tumor cells 
was observed. No difference in the expression of VEGFR2 in the 
treated vs. non treated groups of C38 was detected.  
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We found a significant difference between the microvessel density 
(MVD) of the C26 groups. The post-hoc test showed a suppressed 
MVD by sunitinib, motesanib and minimally vatalanib in that model. 
Microvessel area was also decreased in the sunitinib, motesanib and 
less intensively in the sorafenib treated group. In the C38 model 
however, no difference in the vessel density, but in vessel area was 
detected. It is also important to mention, that major differences in the 
vasculature of the two groups were observed. While C26 tumors had 
lots of small vessels, C38 tumors were characterized by only a few, 
but large and complex vascular structures.  
MVD clearly correlated with tumor oxygenation. Hypoxia was located 
in the less vascularized areas of the tumor. Accordingly, a significant 
increase in the intratumoral hypoxic areas was observed in the 
sunitinib treated group. The ratio of hypoxic areas did not differ in the 
C38 model.  
Besides the inhibition of EC proliferation, multi-target antiangiogenic 
RTKIs also influence PDGFR and FGFR positive pericyte and VMSC 
recruitment to tumor blood vessels. Therefore, the inhibition of these 
receptors may result in not only decreased MVD and consequently 
lower blood flow rate of tumors, but could also facilitate cancer cell 
metastatization. To observe the structural changes of the vasculature 
in response to treatment, we examined the expression of laminin, 
desmin and αSMA of tumor sections. While all vessels remained 
underlaid with a definite layer of laminin and covered with αSMA, 
desmin expression has decreased in response to sunitinib and 
motesanib treatment in the C26 model. Both laminin and αSMA 
expression were definite and did not change in response to 
treatment in the C38 group, but unlike in C26, no difference in 
desmin expression was observed either. 
 
Mass spectrometric analysis 
 
Compound characterization 
To determine if these differences in the biological effects of the 
compounds arise from the differences in the intratumoral drug 
concentrations, we have developed a method to characterize the 
antiangiogenic RTKIs in tissue samples.  
13 
 
First, the quasimolecular ion and fragmentation pattern of each 
compound was defined on a MALDI stainless steel target plate.  
The quasimolecular ion of motesanib was detected at m/z 374.199. 
Fragmentation of the molecule resulted in ions at m/z 212.1, 189.1 and 
163.1.  
Pazopanib was detected at m/z 438.17. Subsequent MS/MS 
fragmentation of the precursor ions led to fragment ions at m/z 421.1, 
357.1, 342.1. 
Sorafenib was found with a quasimolecular ion at m/z 465.093. 
Fragment ions at m/z 447.1, 425.1, 270.2 and 252.2 were detected. 
Sunitinib was identified at m/z 399.218. Subsequent MS/MS 
fragmentation of the precursor ions led to fragment ions at m/z 326.1 
and 283.1. 
The quasimolecular ion of vatalanib was seen at m/z 347.105. 
Fragment ions at m/z 320.2, 311.2, 294.2, 268.1, 254.1 and 220.2 were 
generated. 
When applied to the tissue surface, drug molecules showed similar 
ionization and fragmentation properties to those generated on the 
MALDI plate.  
 
Precursor compound and metabolite detection in the blood 
Adsorption of the drugs was examined in the peripheral blood, drawn 
just before sacrificing the animals. In both models all applied drugs 
absorbed successfully with notable signal intensities being observed in 
the peripheral blood. Besides, different metabolites of the drugs were 
also traceable.  
No difference in the signal intensities and metabolization pattern of 
vatalanib in the blood samples taken from the Balb/C and the 
C57black/6 mice was detected.  
 
Tissue imaging of antiangiogenic RTKIs 
Calibration of the drug molecules resulted in linear correlation 
between concentration and normalized average signal intensity for all 
compounds in the examined concentration range. Based on the 
calibration curves, average signal intensities were translated into drug 
concentration (μmol/mL) data of C26 and C38 tumors. While 
intratumoral sorafenib and vatalanib levels did not differ between 
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drug-treated and control C26 tumors, the concentrations of motesanib, 
pazopanib and sunitinib were significantly elevated (vs. control), with 
the highest values detected in the sunitinib-treated animals.  
Importantly, the above described drug concentrations refer to the 
entire tumor section and striking differences in the drug distribution 
were observable within the in vivo-treated C26 tumors. As for 
sunitinib, the drug was quite homogeneously distributed within the 
viable C26 tumor areas and apoptotic regions showed notably lower 
signal intensities. In contrast, the distribution of motesanib and 
pazopanib was inhomogeneous with the highest signal intensities 
observed in non-viable areas. Only traces of sorafenib and vatalanib 
were detected in the C26 model.  
In a previously published study, the members of our group found 
significantly decreased C38 tumor burdens in C57Bl/6 mice treated 
with vatalanib. Accordingly, in order to determine why mice bearing 
C26 tumors respond notably poorer to vatalanib than those with C38 
tumors, we also utilized MALDI-MSI of C38 tumors and addressed 
whether there are animal model-specific variations in the tumor tissue 
penetration and distribution of antiangiogenic RTKIs. In contrast to 
the C26 model, vatalanib was well-distributed with notable signal 
intensities in the C38 tumors. In line with this, in vatalanib-treated 
mice bearing C38 tumors, the intratumoral drug concentration was 
significantly higher than that in the group of untreated controls. It is 
also important to mention that we found significantly higher vatalanib 
concentrations in C38 than in C26 tumors.  
No correlation between drug signal intensities in the blood and in the 
corresponding tumor tissue was detected.  
We also identified intratumoral metabolites of sunitinib, motesanib 
and vatalanib, however, only in tumors, where the precursor 
molecules were also detectable. 
The precursor compound, its fragment ions and all the measured 
metabolites showed an overlapping tissue pattern. This co-localization 
in case of the fragment ions can be interpreted as a molecular 
fingerprint that confirms the identity of RTKIs.  
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5. CONCLUSIONS 
 
1. Our results provide the first evidence that MALDI-MSI can be 
used to conduct ADME studies on low molecular weight 
antiangiogenic drugs. 
2. Limited tumor tissue drug penetration contributes to primary 
resistance against angiogenesis inhibitors. 
3. Drug concentration detected in the viable regions of the tumor 
is related to the antitumor and antivascular effects of the 
applied compounds.  
4. The effects of antiangiogenic RTKIs are dependent on the 
tumor model used.  
5. Effective treatment in the C26 model, but not the C38 model 
resulted in a decreased expression of VEGFR2 and desmin, 
and an increase in the intratumoral hypoxia. 
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